TUESDAY, June 17, 2025 (HealthDay News) — Individuals with pediatric-onset multiple sclerosis (POMS) have greater epigenetic age and age acceleration residual (AAR) compared with age-similar controls, according to a study published online June 3 in Neurology. Christopher Goyne, M.D., from the University of California, San Diego, and colleagues compared epigenetic age in participants with POMS […]
The post Greater Epigenetic Age Seen in Patients With Pediatric-Onset MS first appeared on Physician’s Weekly.
